Prepared by:
McMaster University Evidence-based Practice Center
McMaster University, Faculty of Health Sciences
Hamilton, Ontario, Canada
Investigators
Pasqualina (Lina) Santaguida, Ph.D.
Parminder Raina, Ph.D.
Lynda Booker, B.A.
Christopher Patterson, M.D.
Fulvia Baldassarre, M.Sc.
David Cowan, M.D.
Mary Gauld, B.A.
Mitch Levine, M.D.
Ayse Unsal, Ph.D.
File Name Description Software Version File Size ________________________________________________________________________________________________ 001front.doc Microsoft Word® Document MS Word® 2002 44KB 3 pages Contents: Title Page, Preface ________________________________________________________________________________________________ 002conts.doc Microsoft Word® Document MS Word® 2002 48KB 5 pages Contents: Table of Contents ________________________________________________________________________________________________ 003body.doc Microsoft Word® Document MS Word® 2002 6.8MB 149 pages Contents: Acknowledgements, Structured Abstract; Chapter 1. Introduction: Diagnosis of Dementia, Analytic Framework: Understanding Therapeutic Aims of Pharmacological Treatment, Figure 1. Pathway for the progression of dementia and the ideal application of drug interventions within this framework, Understanding Efficacy of Pharmacological Interventions in Dementia Trials, Primary Objectives and Scope of Systematic Review; Chapter 2. Methods: The Research Team, Topic Assessment and Refinement, Table 1. Databases searched for relevant RCTs; Chapter 3. Results: Eligible Studies, Question 1: Does pharmacotherapy for dementia syndromes improve cognitive symptoms and outcomes?, Figure 2. Flow diagram showing the final number of studies meeting the eligibility criteria, Figure 3. Proportion of studies as a function of year of publication, Table 2. List of Cholinergic neurotransmitter modifying agents and the number of studies vs. placebo for each of these, Figure 4. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the MMSE comparing carnitine versus placebo, Figure 5. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the MMSE comparing donepezil and placebo, Figure 6. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing donepezil versus placebo, Figure 7. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the CIBC+ (continuous data) comparing donepezil versus placebo, Figure 8. Relative Risk (RR) from the Random Effects Model (Random) for the CIBIC+ (dichotomous data probability of improving) for a 5 mg dose of donepezil, Figure 9. Relative Risk (RR) from the Fixed Effect Model (fixed) for the CIBIC+ (dichotomous data [improved versus not]) for a 10 mg dose of donepezil, Figure 10. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the Clinical Dementia Rating (CDR) comparing donepezil versus placebo, Figure 11. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing galantamine at 24 mg dose versus placebo, Figure 12. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing galantamine at 32 mg dose versus placebo, Figure 13. Relative Risk (RR) from the Random Effects Model (Random) for the CIBIC comparing galantamine at 24 mg dose versus placebo, Figure 14. Relative Risk (RR) from the Fixed Effects Mode Fixed l for CIBIC comparing galantamine at 32 mg dose versus placebo, Figure 15. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the DAD comparing galantamine at 24 mg dose versus placebo, Figure 16. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the DAD comparing galantamine at 32 mg dose versus placebo, Figure 17. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing rivastigmine versus placebo, Figure 18. Relative Risk (RR) from the Random Effects Model (Random) for the CIBIC+ comparing rivastigmine versus placebo, Table 3. List of Non-cholinergic neurotransmitter/neuropeptide modifying agents and the number of studies vs. placebo for each of these, Table 4. List of Other pharmacological agents and the number of studies vs. placebo for each of these, Figure 19. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing cerebrolysin versus placebo, Figure 20. Odd Ratio (OR) from the Random Effects Model (Random) for the CGI comparing cerebrolysin versus placebo, Figure 21. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the MMSE change score comparing propentofylline versus placebo, Figure 22. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the DSST change score comparing propentofylline versus placebo, Question 2: Does pharmacotherapy delay cognitive deterioration or delay disease onset of dementia syndromes?, Table 5. Studies that withdrew the treatment agent but maintained at least single blinding, Table 6. Studies that withdrew treatment and did not specify if blinding for washout or extension was maintained, Question 3: Are certain drugs, including alternative medicines (non-pharmaceutical), more effective than others?, Figure 23. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing donepezil versus placebo, Figure 24. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing galantamine versus placebo, Figure 25. Weighted Mean Difference (WMD) from the Random Effects Model (Random) for the ADAS-cog comparing rivastigmine versus placebo, Figure 26. Weighted Mean Difference (WMD) from the Fixed Effects Model (Fixed) for the ADAS-cog comparing tacrine versus placebo, Figure 27. Relative Risk (RR) from the Random Effects Model (Random) for the CIBIC comparing donepezil versus placebo, Figure 28. Relative Risk (RR) from the Random Effects Model (Random) for the CIBIC comparing galantamine versus placebo, Figure 29. Relative comparison of effect sizes for studies using the CIBIC rivastigmine versus placebo, Figure 30. Relative comparison of effect sizes for studies using the CIBIC comparing tacrine versus placebo, Question 4: Do certain patient populations benefit more from pharmacotherapy than others?, Table 7. Studies with stratified analyses, Question 5: What is the evidence for the treatment of VaD?, Table 8. Studies evaluating vascular dementia patients relative to other dementias, Table 9. Guide to Overall Summary Tables - Outcome Measures Classified by Domain; Summary Evidence Tables: Summary Table 1. Carnitine, Summary Table 2. Donepezil, Summary Table 3. Galantamine, Summary Table 4. Metrifonate, Summary Table 5. Nicergoline, Summary Table 6. Physostigmine, Summary Table 7. Posatirelin, Summary Table 8. Rivastigmine, Summary Table 9. Tacrine, Summary Table 10. Velnacrine, Summary Table 11. Various cholinergic neurotransmitter modifying agents, Summary Table 12. Haloperidol, Summary Table 13. Memantine, Summary Table 14. Selegeline, Summary Table 15. Various non-cholinergic neurotransmitter/neuropeptide modifying agents, Summary Table 16. Cerebrolysin, Summary Table 17. Estrogens, Summary Table 18. Ginkgo Biloba, Summary Table 19. Idebenone, Summary Table 20. Oxiracetam, Summary Table 21. Pentoxifylline, Summary Table 22. Propentofylline, Summary Table 23. Additional pharmacological agents, Summary Table 24. Drug vs drug studies, Summary Table 25. VaD/MID Studies; Chapter 4. Discussion: Strength of the Evidence, Question 1: Does pharmacotherapy for dementia syndromes improve cognitive symptoms and outcomes?, Question 2: Does pharmacotherapy delay cognitive deterioration or delay disease onset of dementia syndromes?, Figure 31. Delay of symptomatic treatment effects, Figure 32. Delay in disease progression treatment effects, Question 3: Are certain drugs, including alternative medicines (including non-pharmaceutical) more effective than others?, Question 4: Do certain patient populations benefit more from pharmacotherapy than others?, Question 5: What is the evidence-base for the treatment of vascular dementia?, Determining Clinical Relevance, Limitations of the McMaster AHRQ Review, Future Research Recommendations, References ________________________________________________________________________________________________ 004acros.doc Microsoft Word® Document MS Word® 2002 314KB 7 pages Contents: Acronyms and Abbreviations ________________________________________________________________________________________________ 005bib.doc Microsoft Word® Document MS Word® 2002 617KB 120 pages Contents: Bibliography ________________________________________________________________________________________________ 006apscv.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Cover Page: Appendixes ________________________________________________________________________________________________ 007apacv.doc Microsoft Word® Document MS Word® 2002 20KB 1 page Contents: Cover Page: Appendix A. Search strategies ________________________________________________________________________________________________ 008appa.doc Microsoft Word® Document MS Word® 2002 61KB 14 pages Contents: Appendix A. Search strategies ________________________________________________________________________________________________ 009apbcv.doc Microsoft Word® Document MS Word® 2002 21KB 1 page Contents: Cover Page: Appendix B. Forms ________________________________________________________________________________________________ 010apb1.doc Microsoft Word® Document MS Word® 2002 31KB 1 page Contents: Full Text Screening Form ________________________________________________________________________________________________ 011apb2.doc Microsoft Word® Document MS Word® 2002 31KB 2 pages Contents: Gudie to Full Text Screening Form ________________________________________________________________________________________________ 012apb3.doc Microsoft Word® Document MS Word® 2002 29KB 1 page Contents: Full Text Screening Form: Secondary Exclusion ________________________________________________________________________________________________ 013apb4.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Quality Score for JADAD Scale and for Modified JADAD Scale ________________________________________________________________________________________________ 014apb5.doc Microsoft Word® Document MS Word® 2002 42KB 2 pages Contents: Table A. Key Characteristics ________________________________________________________________________________________________ 015apb6.doc Microsoft Word® Document MS Word® 2002 35KB 2 pages Contents: Table B. Evidence Results ________________________________________________________________________________________________ 016apb7.doc Microsoft Word® Document MS Word® 2002 23KB 1 page Contents: Overall Summary Table Interpretation ________________________________________________________________________________________________ 017apb8.doc Microsoft Word® Document MS Word® 2002 39KB 2 pages Contents: Reporting Safety information in Randomized controlled trials ________________________________________________________________________________________________ 018apccv.doc Microsoft Word® Document MS Word® 2002 21KB 1 page Contents: Cover Page: Appendix C. Evidence tables ________________________________________________________________________________________________ 019apcgd.doc Microsoft Word® Document MS Word® 2002 108KB 3 pages Contents: Guide to the Results Tables ________________________________________________________________________________________________ 020et1.doc Microsoft Word® Document MS Word® 2002 48KB 3 pages Contents: Evidence Table 1. Key characteristics: Carnitine (ALCAR) ________________________________________________________________________________________________ 021et2.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Evidence Table 2. Study results: Carnitine (ALCAR) ________________________________________________________________________________________________ 022et3.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 3. Study results: Carnitine (ALCAR) ________________________________________________________________________________________________ 023et4.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 4. Study results: Carnitine (ALCAR) ________________________________________________________________________________________________ 024et5.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 5. Study results: Carnitine (ALCAR) ________________________________________________________________________________________________ 025et6.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 6. Study results: Carnitine (ALCAR) ________________________________________________________________________________________________ 026et7.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 7. Study results: Carnitine (ALCAR) ________________________________________________________________________________________________ 027et8.doc Microsoft Word® Document MS Word® 2002 94KB 1 page Contents: Evidence Table 8. Adverse Events: Carnitine (ALCAR) ________________________________________________________________________________________________ 028et9.doc Microsoft Word® Document MS Word® 2002 66KB 4 pages Contents: Evidence Table 9. Key characteristics: Donepezil (DPZ) ________________________________________________________________________________________________ 029et10.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 10. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 030et11.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Evidence Table 11. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 031et12.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 12. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 032et13.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 13. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 033et14.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 14. Study results: Denepezil ________________________________________________________________________________________________ 034et15.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 15. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 035et16.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 16. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 036et17.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 17. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 037et18.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 18. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 038et19.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 19. Study results: Donepezil (DPZ), Vitamin E ________________________________________________________________________________________________ 039et20.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 20. Study results: Donepezil (DPZ) ________________________________________________________________________________________________ 040et21.doc Microsoft Word® Document MS Word® 2002 100KB 1 page Contents: Evidence Table 21. Adverse Events: Donepezil (DPZ) ________________________________________________________________________________________________ 041et22.doc Microsoft Word® Document MS Word® 2002 45KB 2 pages Contents: Evidence Table 22. Key characteristics: Galantamine ________________________________________________________________________________________________ 042et23.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 23. Study results: Galantamine ________________________________________________________________________________________________ 043et24.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 24. Study results: Galantamine ________________________________________________________________________________________________ 044et25.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 25. Study results: Galantamine ________________________________________________________________________________________________ 045et26.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 26. Study results: Galantamine ________________________________________________________________________________________________ 046et27.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 27. Study results: Galantamine ________________________________________________________________________________________________ 047et28.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 28. Study results: Galantamine ________________________________________________________________________________________________ 048et29.doc Microsoft Word® Document MS Word® 2002 94KB 1 page Contents: Evidence Table 29. Adverse Events: Galantamine ________________________________________________________________________________________________ 049et30.doc Microsoft Word® Document MS Word® 2002 62KB 5 pages Contents: Evidence Table 30. Key characteristics. Metrifonate ________________________________________________________________________________________________ 050et31.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 31. Study results: Metrifonate ________________________________________________________________________________________________ 051et32.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 32. Study results: Metrifonate ________________________________________________________________________________________________ 052et33.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 33. Study results: Metrifonate ________________________________________________________________________________________________ 053et34.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 34. Study results: Metrifonate ________________________________________________________________________________________________ 054et35.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 35. Study results: Metrifonate ________________________________________________________________________________________________ 055et36.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 36. Study results: Metrifonate ________________________________________________________________________________________________ 056et37.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 37. Study results: Metrifonate ________________________________________________________________________________________________ 057et38.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 38. Study results: Metrifonate ________________________________________________________________________________________________ 058et39.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 39. Study results: Metrifonate ________________________________________________________________________________________________ 059et40.doc Microsoft Word® Document MS Word® 2002 89KB 1 page Contents: Evidence Table 40. Adverse Events: Metrifonate ________________________________________________________________________________________________ 060et41.doc Microsoft Word® Document MS Word® 2002 42KB 2 pages Contents: Evidence Table 41. Key characteristics: Nicergoline ________________________________________________________________________________________________ 061et42.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 42. Study results: Nicergoline ________________________________________________________________________________________________ 062et43.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 43. Study results: Nicergoline ________________________________________________________________________________________________ 063et44.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 44. Study results: Nicergoline ________________________________________________________________________________________________ 064et45.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 45. Study results: Nicergoline ________________________________________________________________________________________________ 065et46.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 46. Study results: Nicergoline - Antagonic Stress ________________________________________________________________________________________________ 066et47.doc Microsoft Word® Document MS Word® 2002 79KB 1 page Contents: Evidence Table 47. Adverse Events: Nicergoline ________________________________________________________________________________________________ 067et48.doc Microsoft Word® Document MS Word® 2002 39KB 2 pages Contents: Evidence Table 48. Key characteristics: Physostigmine ________________________________________________________________________________________________ 068et49.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 49. Study results: Physostigmine ________________________________________________________________________________________________ 069et50.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 50. Study results: Physostigmine ________________________________________________________________________________________________ 070et51.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 51. Study results: Physostigmine ________________________________________________________________________________________________ 071et52.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 52. Study results: Physostigmine ________________________________________________________________________________________________ 072et53.doc Microsoft Word® Document MS Word® 2002 67KB 1 page Contents: Evidence Table 53. Adverse Events: Physostigmine ________________________________________________________________________________________________ 073et54.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 54. Key characteristics: Posatirelin ________________________________________________________________________________________________ 074et55.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 55. Study results: Posatirelin ________________________________________________________________________________________________ 075et56.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 56. Study results: Posatirelin ________________________________________________________________________________________________ 076et57.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 57. Study results: Posatirelin ________________________________________________________________________________________________ 077et58.doc Microsoft Word® Document MS Word® 2002 45KB 1 page Contents: Evidence Table 58. Study results: Citicoline - Posatirelin ________________________________________________________________________________________________ 078et59.doc Microsoft Word® Document MS Word® 2002 66KB 1 page Contents: Evidence Table 59. Adverse Events: Posatirelin ________________________________________________________________________________________________ 079et60.doc Microsoft Word® Document MS Word® 2002 49KB 3 pages Contents: Evidence Table 60. Key characteristics: Rivastigmine ________________________________________________________________________________________________ 080et61.doc Microsoft Word® Document MS Word® 2002 46KB 2 pages Contents: Evidence Table 61. Study results: Rivastigmine ________________________________________________________________________________________________ 081et62.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 62. Study results: Rivastigmine ________________________________________________________________________________________________ 082et63.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 63. Study results: Rivastigmine ________________________________________________________________________________________________ 083et64.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 64. Study results: Rivastigmine ________________________________________________________________________________________________ 084et65.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 65. Study results: Rivastigmine ________________________________________________________________________________________________ 085et66.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 66. Study results: Rivastigmine ________________________________________________________________________________________________ 086et67.doc Microsoft Word® Document MS Word® 2002 94KB 1 page Contents: Evidence Table 67. Adverse Events: Rivastigmine ________________________________________________________________________________________________ 087et68.doc Microsoft Word® Document MS Word® 2002 59KB 4 pages Contents: Evidence Table 68. Key characteristics: Tacrine ________________________________________________________________________________________________ 088et69.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 69. Study results: Tacrine ________________________________________________________________________________________________ 089et70.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 70. Study results: Idebenone-Tacrine ________________________________________________________________________________________________ 090et71.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 71. Study results: Tacrine ________________________________________________________________________________________________ 091et72.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 72. Study results: Tacrine & Lethicin ________________________________________________________________________________________________ 092et73.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 73. Study results: Tacrine ________________________________________________________________________________________________ 093et74.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 74. Study results: Tetrahydroaminoacridine & Lethicin ________________________________________________________________________________________________ 094et75.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 75. Study results: Tacrine ________________________________________________________________________________________________ 095et76.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 76. Study results: Tacrine ________________________________________________________________________________________________ 096et77.doc Microsoft Word® Document MS Word® 2002 86KB 1 page Contents: Evidence Table 77. Adverse Events: Tacrine ________________________________________________________________________________________________ 097et78.doc Microsoft Word® Document MS Word® 2002 31KB 1 page Contents: Evidence Table 78. Key characteristics: Velnacrine ________________________________________________________________________________________________ 098et79.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 79. Study results: Velnacrine ________________________________________________________________________________________________ 099et80.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 80. Study results: HP 128 (Velnarcrine) ________________________________________________________________________________________________ 100et81.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 81. Study results: Velnacrine ________________________________________________________________________________________________ 101et82.doc Microsoft Word® Document MS Word® 2002 62KB 1 page Contents: Evidence Table 82. Adverse Events: Velnacrine ________________________________________________________________________________________________ 102et83.doc Microsoft Word® Document MS Word® 2002 52KB 2 pages Contents: Evidence Table 83. Key Characteristics: Various cholinergic neurotransmitter modifying agents ________________________________________________________________________________________________ 103et84.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 84. Study results: Eptastigmine ________________________________________________________________________________________________ 104et85.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 85. Study results: Eptastigmine ________________________________________________________________________________________________ 105et86.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 86. Study results: Haboyin (Huperzine-A) ________________________________________________________________________________________________ 106et87.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 87. Study results: Linopirdine ________________________________________________________________________________________________ 107et88.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 88. Study results: Linopirdine ________________________________________________________________________________________________ 108et89.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 89. Study results: Sabeluzole ________________________________________________________________________________________________ 109et90.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 90. Study results: Antagonic Stress - Meclofenoxate ________________________________________________________________________________________________ 110et91.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 91. Study results: Nicergoline - Antagonic Stress ________________________________________________________________________________________________ 111et92.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 92. Study results: Huperzine A ________________________________________________________________________________________________ 112et93.doc Microsoft Word® Document MS Word® 2002 94KB 1 page Contents: Evidence Table 93. Adverse Events: Neurotransmitters - Various Cholinergic neurotransmitter modifying agents ________________________________________________________________________________________________ 113et94.doc Microsoft Word® Document MS Word® 2002 53KB 3 pages Contents: Evidence Table 94. Key characteristics: Haloperidol ________________________________________________________________________________________________ 114et95.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 95. Study results: Haloperidol - Tiapride ________________________________________________________________________________________________ 115et96.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 96. Study results: Haloperidol - Fluoxetine ________________________________________________________________________________________________ 116et97.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 97. Study results: Risperidone - Haloperidol ________________________________________________________________________________________________ 117et98.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 98. Study results: Loxapine - Haloperidol ________________________________________________________________________________________________ 118et99.doc Microsoft Word® Document MS Word® 2002 45KB 2 pages Contents: Evidence Table 99. Study results: Haloperidol - Trazodone ________________________________________________________________________________________________ 119et100.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 100. Study results: Loxapine - Haloperidol ________________________________________________________________________________________________ 120et101.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 101. Study results: Haloperidol - Oxazepam - Diphenhydramine ________________________________________________________________________________________________ 121et102.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 102. Study results: Haloperidol - Risperidone ________________________________________________________________________________________________ 122et103.doc Microsoft Word® Document MS Word® 2002 125KB 2 pages Contents: Evidence Table 103. Adverse Events: Haloperidol ________________________________________________________________________________________________ 123et104.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 104. Key characteristics: Memantine ________________________________________________________________________________________________ 124et105.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 105. Study results: Memantine ________________________________________________________________________________________________ 125et106.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 106. Study results: Memantine ________________________________________________________________________________________________ 126et107.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 107. Study results: Memantine ________________________________________________________________________________________________ 127et108.doc Microsoft Word® Document MS Word® 2002 63KB 1 page Contents: Evidence Table 108. Adverse Events: Memantine ________________________________________________________________________________________________ 128et109.doc Microsoft Word® Document MS Word® 2002 45KB 2 pages Contents: Evidence Table 109. Key characteristics: Selegiline ________________________________________________________________________________________________ 129et110.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 110. Study results: Selegiline ________________________________________________________________________________________________ 130et111.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 111. Study results: Selegeline ________________________________________________________________________________________________ 131et112.doc Microsoft Word® Document MS Word® 2002 47KB 2 pages Contents: Evidence Table 112. Study results: Selegiline ________________________________________________________________________________________________ 132et113.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 113. Study results: Selegiline ________________________________________________________________________________________________ 133et114.doc Microsoft Word® Document MS Word® 2002 46KB 2 pages Contents: Evidence Table 114. Study results: Selegeline ________________________________________________________________________________________________ 134et115.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 115. Study results: Selegiline - Vitamin E ________________________________________________________________________________________________ 135et116.doc Microsoft Word® Document MS Word® 2002 93KB 1 page Contents: Evidence Table 116. Adverse Events: Selegiline ________________________________________________________________________________________________ 136et117.doc Microsoft Word® Document MS Word® 2002 184KB 13 pages Contents: Evidence Table 117. Key Characteristics. Various non-cholinergic neurotransmitter/ neuropeptide modifying agents ________________________________________________________________________________________________ 137et118.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 118. Study results: Alaproclate ________________________________________________________________________________________________ 138et119.doc Microsoft Word® Document MS Word® 2002 41KB 2 pages Contents: Evidence Table 119. Study results: Anapsos ________________________________________________________________________________________________ 139et120.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 120. Study results: BMY-21,502 ________________________________________________________________________________________________ 140et121.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 121. Study results: Carbamazepine ________________________________________________________________________________________________ 141et122.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 122. Study results: Carbamazepine ________________________________________________________________________________________________ 142et123.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 123 Study results: Citalopram ________________________________________________________________________________________________ 143et124.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 124. Study results: Citalopram ________________________________________________________________________________________________ 144et125.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 125. Study results: Divalproex ________________________________________________________________________________________________ 145et125.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 125. Study results: Divalproex ________________________________________________________________________________________________ 146et126.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 126. Study results: Divalproex ________________________________________________________________________________________________ 147et127.doc Microsoft Word® Document MS Word® 2002 44KB 2 pages Contents: Evidence Table 127. Study results: Fluvoxamine ________________________________________________________________________________________________ 148et127.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 127. Study results: Fluvoxamine ________________________________________________________________________________________________ 149et128.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 128. Study results: Imipramine ________________________________________________________________________________________________ 150et129.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 129. Study results: Lisuride ________________________________________________________________________________________________ 151et130.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 130. Study results: Lu25-109 ________________________________________________________________________________________________ 152et131.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 131. Study results: Maprotiline ________________________________________________________________________________________________ 153et132.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 132. Study results: Minaprine ________________________________________________________________________________________________ 154et133.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 133. Study results: Moclobemide ________________________________________________________________________________________________ 155et134.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 134. Study results: Naftidrofuryl ________________________________________________________________________________________________ 156et135.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 135. Study results: Olanzapine ________________________________________________________________________________________________ 157et136.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Evidence Table 136. Study results: Phosphatidylserine (PS) ________________________________________________________________________________________________ 158et137.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 137. Study results: Phosphatidylserine ________________________________________________________________________________________________ 159et138.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 138. Study results: Sertraline ________________________________________________________________________________________________ 160et139.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 139. Study results: Sertraline ________________________________________________________________________________________________ 161et140.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 140. Study results: Fluoxetine ________________________________________________________________________________________________ 162et141.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 142. Study results: Risperidone ________________________________________________________________________________________________ 163et142.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 142. Study results: Risperidone ________________________________________________________________________________________________ 164et143.doc Microsoft Word® Document MS Word® 2002 43KB 2 pages Contents: Evidence Table 143. Study results: Haloperidol - Trazodone ________________________________________________________________________________________________ 165et144.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 144. Study results: Risperidone - Haloperidol ________________________________________________________________________________________________ 166et145.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 145. Study results: Haloperidol - Tiapride ________________________________________________________________________________________________ 167et146.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 146. Study results: Olanzapine - Lorazepam ________________________________________________________________________________________________ 168et147.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 147. Study results: Thoridazine - Loxapine ________________________________________________________________________________________________ 169et148.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 148. Study results: Citalopram ________________________________________________________________________________________________ 170et149.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 149. Study results: Xanomeline Tartrate (XT) ________________________________________________________________________________________________ 171et150.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 150. Study results: Haloperidol - Risperidone ________________________________________________________________________________________________ 172et151.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 151. Study results: Fluoxetine ________________________________________________________________________________________________ 173et152.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 152. Study results: Lorazepam, Alprazolam ________________________________________________________________________________________________ 174et153.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 153. Study results: Citalopram ________________________________________________________________________________________________ 175et154.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 154. Study results: Haloperidol - Oxazepam - Diphenhydramine ________________________________________________________________________________________________ 176et155.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 155. Study results: Loxapine - Haloperidol ________________________________________________________________________________________________ 177et156.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 156. Study results: 5'-MTHF - Trazodone ________________________________________________________________________________________________ 178et157.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 157. Study results: Tiapride - Melperone ________________________________________________________________________________________________ 179et158.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 158. Study results: Imipramine - Paroxetine ________________________________________________________________________________________________ 180et159.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 159. Study results: Loxapine - Haloperidol ________________________________________________________________________________________________ 181et160.doc Microsoft Word® Document MS Word® 2002 437KB 6 pages Contents: Evidence Table 160. Adverse events. Various cholinergic neurotransmitter modifying agents ________________________________________________________________________________________________ 182et161.doc Microsoft Word® Document MS Word® 2002 44KB 2 pages Contents: Evidence Table 161. Key characteristics: Cerebrolysin (CERE) ________________________________________________________________________________________________ 183et162.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 162. Study results: Cerebrolysin (CERE) ________________________________________________________________________________________________ 184et163.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 163. Study results: Cerebrolysin (CERE) ________________________________________________________________________________________________ 185et164.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 164. Study results: Cerebrolysin (CERE) ________________________________________________________________________________________________ 186et165.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 165. Study results: Cerebrolysin (CERE) ________________________________________________________________________________________________ 187et166.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 166. Study results: Cerebrolysin (CERE) ________________________________________________________________________________________________ 188et167.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Evidence Table 167. Study results: Cerebrolysin (CERE) ________________________________________________________________________________________________ 189et168.doc Microsoft Word® Document MS Word® 2002 93KB 1 page Contents: Evidence Table 168. Adverse Events: Cerebrolysin (CERE) ________________________________________________________________________________________________ 190et169.doc Microsoft Word® Document MS Word® 2002 45KB 3 pages Contents: Evidence Table 169. Key characteristics: Estrogens ________________________________________________________________________________________________ 191et170.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 170. Study results: Estradiol ________________________________________________________________________________________________ 192et171.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 171. Study results: Estrogen ________________________________________________________________________________________________ 193et172.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 172. Study results: Estrogen ________________________________________________________________________________________________ 194et173.doc Microsoft Word® Document MS Word® 2002 52KB 3 pages Contents: Evidence Table 173. Study results: Estrogen ________________________________________________________________________________________________ 195et174.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 174. Study results: Estrogen ________________________________________________________________________________________________ 196et175.doc Microsoft Word® Document MS Word® 2002 78KB 1 page Contents: Evidence Table 175. Adverse Events: Estrogens ________________________________________________________________________________________________ 197et176.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 176. Key characteristics: Gingko Biloba ________________________________________________________________________________________________ 198et177.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 177. Study results: Ginkgo Biloba (EGb761) ________________________________________________________________________________________________ 199et178.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 178. Study results: Ginkgo Biloba (EGb761) ________________________________________________________________________________________________ 200et179.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 179. Study results: Ginkgo Biloba (EGb761, Tebonin forte) ________________________________________________________________________________________________ 201et180.doc Microsoft Word® Document MS Word® 2002 63KB 1 page Contents: Evidence Table 180. Adverse Events: Gingko Biloba ________________________________________________________________________________________________ 202et181.doc Microsoft Word® Document MS Word® 2002 42KB 2 pages Contents: Evidence Table 181. Key characteristics: Idebenone ________________________________________________________________________________________________ 203et182.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 182. Study results: Idebenone ________________________________________________________________________________________________ 204et183.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 183. Study results: Idebenone ________________________________________________________________________________________________ 205et184.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 184. Study results: Idebenone-Tacrine ________________________________________________________________________________________________ 206et185.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 185. Study results: Idebenone ________________________________________________________________________________________________ 207et186.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 186. Study results: Idebenone ________________________________________________________________________________________________ 208et187.doc Microsoft Word® Document MS Word® 2002 81KB 1 page Contents: Evidence Table 187. Adverse Events: Idebenone ________________________________________________________________________________________________ 209et188.doc Microsoft Word® Document MS Word® 2002 42KB 2 pages Contents: Evidence Table 188. Key characteristics: Oxiracetam ________________________________________________________________________________________________ 210et189.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 189. Study results: Oxiracetem ________________________________________________________________________________________________ 211et190.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 190. Study results: Oxiracetem ________________________________________________________________________________________________ 212et191.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 191. Study results: Oxiracetem ________________________________________________________________________________________________ 213et192.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 192. Study results: Oxiracetem ________________________________________________________________________________________________ 214et193.doc Microsoft Word® Document MS Word® 2002 39KB 1 page Contents: Evidence Table 193. Study results: Oxiracetem ________________________________________________________________________________________________ 215et194.doc Microsoft Word® Document MS Word® 2002 77KB 1 page Contents: Evidence Table 194. Adverse Events: Oxiracetam ________________________________________________________________________________________________ 216et195.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 195. Key characteristics. Pentoxifylline ________________________________________________________________________________________________ 217et196.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 196. Study results: Pentoxifylline ________________________________________________________________________________________________ 218et197.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 197. Study results: Pentoxifylline ________________________________________________________________________________________________ 219et198.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 198. Study results: Oxpentifylline ________________________________________________________________________________________________ 220et199.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 199. Study results: Sulodexide - Pentoxifylline ________________________________________________________________________________________________ 221et200.doc Microsoft Word® Document MS Word® 2002 69KB 1 page Contents: Evidence Table 200. Adverse Events. Pentoxifylline ________________________________________________________________________________________________ 222et201.doc Microsoft Word® Document MS Word® 2002 40KB 2 pages Contents: Evidence Table 201. Key characteristics: Propentofylline ________________________________________________________________________________________________ 223et202.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 202. Study results: Propentofylline ________________________________________________________________________________________________ 224et203.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 203. Study results: Propentofylline ________________________________________________________________________________________________ 225et204.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 204. Study results: Propentofylline ________________________________________________________________________________________________ 226et205.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 205. Study results: Propentofylline ________________________________________________________________________________________________ 227et206.doc Microsoft Word® Document MS Word® 2002 67KB 1 page Contents: Evidence Table 206. Adverse Events: Propentofylline ________________________________________________________________________________________________ 228et207.doc Microsoft Word® Document MS Word® 2002 173KB 12 pages Contents: Evidence Table 207. Key characteristics: Other agents ________________________________________________________________________________________________ 229et208.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 208. Study results: Aniracetam ________________________________________________________________________________________________ 230et209.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 209. Study results: Ateroid ________________________________________________________________________________________________ 231et210.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 210. Study results: BMY 21,502 ________________________________________________________________________________________________ 232et211.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 211. Study results: Buflomedil ________________________________________________________________________________________________ 233et212.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 212. Study results: CBM 36-733 (Ergokryptine) ________________________________________________________________________________________________ 234et213.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 213. Study results: Choto-san ________________________________________________________________________________________________ 235et214.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 214. Study results: Choto-san ________________________________________________________________________________________________ 236et215.doc Microsoft Word® Document MS Word® 2002 42KB 1 page Contents: Evidence Table 215. Study results: Cyclandelate ________________________________________________________________________________________________ 237et216.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 216. Study results: Cyclandelate ________________________________________________________________________________________________ 238et217.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 217. Study results: Desamino-D-Arginine-Vasapressin (DDAVP) ________________________________________________________________________________________________ 239et218.doc Microsoft Word® Document MS Word® 2002 43KB 1 page Contents: Evidence Table 218. Study results: Dihydroergokryptine (DEK) ________________________________________________________________________________________________ 240et219.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 219. Study results: Denbufylline ________________________________________________________________________________________________ 241et220.doc Microsoft Word® Document MS Word® 2002 33KB 1 page Contents: Evidence Table 220. Study results: Desferrioxamine ________________________________________________________________________________________________ 242et221.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 221. Study results: Diclofenac and Misoprostol (D/M) ________________________________________________________________________________________________ 243et222.doc Microsoft Word® Document MS Word® 2002 40KB 1 page Contents: Evidence Table 222. Study results: Glycoaminoglycan ________________________________________________________________________________________________ 244et223.doc Microsoft Word® Document MS Word® 2002 47KB 2 pages Contents: Evidence Table 223. Study results: Monosialotetrahexosylgan (GM-1) ________________________________________________________________________________________________ 245et224.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 224. Study results: Guanfacine ________________________________________________________________________________________________ 246et225.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 225. Study results: Hydergine-LC ________________________________________________________________________________________________ 247et226.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 226. Study results: Hydroxychloroquine ________________________________________________________________________________________________ 248et227.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 227. Study results: Indomethacin ________________________________________________________________________________________________ 249et228.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 228. Study results: N-acetylcysteine (NAC) ________________________________________________________________________________________________ 250et229.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 229. Study results: Nimesulide ________________________________________________________________________________________________ 251et230.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 230. Study results: Nimodipine ________________________________________________________________________________________________ 252et231.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 231. Study results: Nimodipine ________________________________________________________________________________________________ 253et232.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 232. Study results: Nizatidine ________________________________________________________________________________________________ 254et233.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 233. Study results: ACTH4-9 (Org 2766) ________________________________________________________________________________________________ 255et234.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 234. Study results: ACTH 4-9 (Org 2766) ________________________________________________________________________________________________ 256et235.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 235. Study results: Prednisone ________________________________________________________________________________________________ 257et236.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 236. Study results: Simvastatin ________________________________________________________________________________________________ 258et237.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 237. Study results: Thiamine ________________________________________________________________________________________________ 259et238.doc Microsoft Word® Document MS Word® 2002 41KB 1 page Contents: Evidence Table 238. Study results: Vincamine ________________________________________________________________________________________________ 260et239.doc Microsoft Word® Document MS Word® 2002 37KB 1 page Contents: Evidence Table 239. Study results: Piracetam ________________________________________________________________________________________________ 261et240.doc Microsoft Word® Document MS Word® 2002 39KB 2 pages Contents: Evidence Table 240. Study results: Xantinolnicotinate ________________________________________________________________________________________________ 262et241.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 241. Study results: Donepezil (DPZ) - Vitamin E ________________________________________________________________________________________________ 263et242.doc Microsoft Word® Document MS Word® 2002 34KB 1 page Contents: Evidence Table 242. Study results: Fluoxetine ________________________________________________________________________________________________ 264et243.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 243. Study results: 5'-MTHF - Trazodone ________________________________________________________________________________________________ 265et244.doc Microsoft Word® Document MS Word® 2002 48KB 2 pages Contents: Evidence Table 244. Study results: Citicoline ________________________________________________________________________________________________ 266et245.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 245. Study results: Pyritinol - Hydergine ________________________________________________________________________________________________ 267et246.doc Microsoft Word® Document MS Word® 2002 38KB 1 page Contents: Evidence Table 246. Study results: Sulfomucopolysaccharides - Cytidine Diphosphocholine ________________________________________________________________________________________________ 268et247.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Evidence Table 247. Study results: Sulodexide - Pentoxifylline ________________________________________________________________________________________________ 269et248.doc Microsoft Word® Document MS Word® 2002 36KB 1 page Contents: Evidence Table 248. Study results: Selegiline - Vitamin E ________________________________________________________________________________________________ 270et249.doc Microsoft Word® Document MS Word® 2002 414KB 6 pages Contents: Evidence Table 249. Adverse Events: Other agents ________________________________________________________________________________________________ 271apdcv.doc Microsoft Word® Document MS Word® 2002 21KB 1 page Contents: Cover Page: Appendix D. Peer review ________________________________________________________________________________________________ 272apd1.doc Microsoft Word® Document MS Word® 2002 26KB 1 page Contents: Peer Reviewers for the Treatment of Dementia Report ________________________________________________________________________________________________ 273apd2.doc Microsoft Word® Document MS Word® 2002 29KB 2 pages Contents: Structured format for collecting referee comments ________________________________________________________________________________________________ 274apecv.doc Microsoft Word® Document MS Word® 2002 20KB 1 page Contents: Cover Page: Appendix E. Outcome measures ________________________________________________________________________________________________ 275appe.doc Microsoft Word® Document MS Word® 2002 203KB 9 pages Contents: Appendix E. Outcome Measures ________________________________________________________________________________________________ 276apfcv.doc Microsoft Word® Document MS Word® 2002 21KB 1 page Contents: Cover Page: Appendix F. List of excluded studies ________________________________________________________________________________________________ 277appf.doc Microsoft Word® Document MS Word® 2002 561KB 90 pages Contents: Appendix F. List of excluded studies ________________________________________________________________________________________________
AHRQ Publication No. 04-E018-2
Current as of April 2004
Internet Citation:
Pharmacological Treatment of Dementia. File Inventory, Evidence Report/Technology Assessment Number 97. AHRQ Publication No. 04-E018-2, April 2004. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/demphinv.htm
Return to Evidence-based Practice
Clinical Information
AHRQ Home Page
Department of Health and Human Services